54998-00-4Relevant articles and documents
Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor
-
Paragraph 0066; 0070-0074; 0077, (2021/06/13)
The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)
Selective hydrogenation of nitroarenes under mild conditions by the optimization of active sites in a well defined Co?NC catalyst
Chen, Shuo,Jiang, Hong,Jiang, Shun-Feng,Ling, Li-Li
supporting information, p. 5730 - 5741 (2020/09/21)
The catalytic hydrogenation of aromatic nitro compounds containing multiple functional groups into amino compounds with high conversion rates, selectivity, and stability under mild conditions is a great challenge. Herein, a well defined catalyst (Co?NC) is prepared through the pyrolysis of the Co-centered metal-organic framework (MOF) at the optimized temperature. The as-synthesized catalyst exhibits a high conversion rate and selectivity for the hydrogenation of 12 aromatic nitro compounds with different competing groups into desired amino compounds with hydrazine hydrate under mild conditions (80 °C, 30 min, and 1 atm). The catalyst also shows excellent stability and can be reused over 20 times without considerably losing its activity. It is found that the Co-Nx site is the main active site for catalytic hydrogenation, and the Mott-Schottky effect between the surface Co NPs and N-doped carbon can further promote the hydrogenation reaction. EXAFS, TEM, XPS, and Raman analyses confirm that cobalt nanoparticles (NPs) are properly encapsulated by the N-doped carbon matrix at the optimized temperature, and the Co species maintain a high spin state after the catalysis, which may be responsible for the high performance of Co?NC. This work demonstrates not only a highly efficient catalyst for hydrogenation under mild conditions, but also provides insight into the active sites in Co-based catalysts for hydrogenation.
Targeting G-quadruplex DNA structures in the telomere and oncogene promoter regions by benzimidazole?carbazole ligands
Kaulage, Mangesh H.,Maji, Basudeb,Pasadi, Sanjeev,Ali, Asfa,Bhattacharya, Santanu,Muniyappa
, p. 178 - 194 (2018/02/20)
Recent studies support the idea that G-quadruplex structures in the promoter regions of oncogenes and telomere DNA can serve as potential therapeutic targets in the treatment of cancer. Accordingly, several different types of organic small molecules that stabilize G-quadruplex structures and inhibit telomerase activity have been discerned. Here, we describe the binding of benzimidazole-carbazole ligands to G-quadruplex structures formed in G-rich DNA sequences containing the promoter regions of human c-MYC, c-KIT1, c-KIT2, VEGF and BCL2 proto-oncogenes. The fluorescence spectroscopic data indicate that benzimidazole-carbazole ligands bind and stabilize the G-quadruplexes in the promoter region of oncogenes. The molecular docking studies provide insights into the mode and extent of binding of this class of ligands to the G-quadruplexes formed in oncogene promoters. The high stability of these G-quadruplex structures was validated by thermal denaturation and telomerase-catalyzed extension of the 3' end. Notably, benzimidazole-carbazole ligands suppress the expression of oncogenes in cancer cells in a dose-dependent manner. We anticipate that benzimidazole-carbazole ligands, by virtue of their ability to stabilize G-quadruplex structures in the promoter regions of oncogenes, might reduce the risk of cancer through the loss of function in the proteins encoded by these genes.
